In a recent InvestorIntel interview, Tracy Weslosky spoke with Chris Thompson, President of eResearch Corp. about his 25-page Update Equity Research Report on XORTX Therapeutics Inc. (CSE: XRX | NASDAQ: XRTX | FSE: ANU).
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Chris Thompson said that XORTX is a biotech pharma company, which is taking an existing drug, Oxypurinol, and repurposing it to develop two, unique, proprietary therapies, which could help to solve medical needs related to elevated uric acid and its effects on the kidneys without incurring the high cost of basic research. Using its optimization technology, XORTX is developing multiple drug treatments for acute kidney injury including the type of kidney injury found in COVID-19 patients. With two drugs in stage 3 clinical trials, Chris told InvestorIntel that XORTX is “significantly undervalued” when compared to its peer companies.
To watch the full interview, click here
About eResearch Corporation
eResearch Corporation is a respected source for, institutional-quality, equity research focused primarily on small- and mid-cap companies. The purpose of the focus is to identify companies that have interesting prospects, sound management, and a significant potential for share price appreciation. eResearch complements its corporate research coverage with a diversified selection of informative, insightful, and thought-provoking research publications from a wide variety of investment professionals. The professional investment research and analysis is provided directly to the company’s subscriber network of discerning investors, and is done electronically through its website, www.eresearch.com.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and XRx-101 for Coronavirus / COVID-19 infection. Its XRx-225 is in a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid, the material that forms kidney stones. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
To learn more about XORTX Therapeutics Inc., click here
Disclaimer: This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please email [email protected].
Leave a Reply